Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data
- 1 February 2005
- journal article
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 54 (2) , 197-205
- https://doi.org/10.1099/jmm.0.45773-0
Abstract
In a pilot study, the feasibility of immune whey protein concentrate (40 %; immune WPC-40) to aid the prevention of relapse of Clostridium difficile diarrhoea was evaluated. Immune WPC-40 was made from milk after immunization of Holstein–Frisian cows with C. difficile-inactivated toxins and killed whole-cell C. difficile. Immune WPC-40 contained a high concentration of specific sIgA antibodies, and was effective in neutralizing the cytotoxic effect of C. difficile toxins in cell assays in vitro. Immune WPC-40 conferred protection from otherwise lethal C. difficile-associated caecitis in hamsters. To obtain preliminary data in humans, 16 patients (10 male; median 57 years) with toxin- and culture-confirmed C. difficile diarrhoea were enrolled in an uncontrolled cohort study. Nine had a history of relapsing C. difficile diarrhoea. After completion of standard antibiotic treatment, the patients received immune WPC-40 TID for 2 weeks; it was well tolerated and no treatment-related adverse effects were observed. In all but one case, C. difficile toxins had disappeared from the faeces upon completion of treatment. During a follow-up period of median 333 days (range 35 days to 1 year), none of the patients had suffered another episode of C. difficile diarrhoea. These preliminary data suggest that immune whey protein concentrate-40 may be of help in the prevention of relapse of C. difficile diarrhoea.Keywords
This publication has 32 references indexed in Scilit:
- RecurrentClostridium difficileColitis: Case Series Involving 18 Patients Treated with Donor Stool Administered via a Nasogastric TubeClinical Infectious Diseases, 2003
- Intestinal IgA synthesis: regulation of front-line body defencesNature Reviews Immunology, 2003
- Epidemiology of Clostridium difficile-associated infectionsClinical Microbiology & Infection, 2001
- GT160-246, a Toxin Binding Polymer for Treatment of Clostridium difficile ColitisAntimicrobial Agents and Chemotherapy, 2001
- Risk factors for Clostridium difficile infectionJournal of Hospital Infection, 1998
- Clostridium difficile ColitisNew England Journal of Medicine, 1994
- New selective medium for isolating Clostridium difficile from faeces.Journal of Clinical Pathology, 1992
- Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxinThe Journal of Pediatrics, 1991
- Nosocomial Acquisition ofClostridium difficileInfectionNew England Journal of Medicine, 1989
- Pseudomembranous ColitisPublished by American Medical Association (AMA) ,1975